Cardiovascular disease is the list of free medicines

Cardiovascular diseases: your health is important to us!Do you suffer from cardiovascular diseases? You know that you have, under certain conditions, on a list of free medicines to claim?We want to help you improve your well-being — without unnecessary financial burdens. Many important drugs for the treatment of:High blood pressure,Heart failure,coronary heart disease,Arrhythmias and other cardiovascular disordersin certain cases, available free of charge.What you need to do?You can visit your family doctor or a specialist in cardiology, he can diagnose your condition and prescribe the necessary medication.Check with your insurance provider if you fall on the list of Eligible for free medication.Get the recipe at the pharmacy, often you are able to obtain the medication immediately and without any additional payment.Why is this important?Regular intake of the prescribed medication can:the risk of heart attacks and strokes, reduce,Your blood pressure levels stabilize,Their quality of life significantly improved.Don't wait — act!You still speak with your doctor about your options. Your heart deserves the best care and you deserve to live healthy and free of symptoms.Your health begins with the first step. Take your Chance to free medicines for a healthier Tomorrow!

Madalas nagtatanong ang mga tao sa mga botika tungkol sa mga gamot laban sa presyon ng bagong henerasyon na walang side effects. Pero sa totoong buhay, hindi ito nangyayari. Lahat ng epektibong gamot ay may kanya-kanyang side effects. Kailangan mong maglaan ng maraming oras kasama ang iyong doktor para piliin ang tamang grupo ng gamot laban sa high blood pressure para sa'yo. Cardiovascular disease is the list of free medicines. Madalas nagtatanong ang mga tao sa mga botika tungkol sa mga gamot laban sa presyon ng bagong henerasyon na walang side effects. Pero sa totoong buhay, hindi ito nangyayari. Lahat ng epektibong gamot ay may kanya-kanyang side effects. Kailangan mong maglaan ng maraming oras kasama ang iyong doktor para piliin ang tamang grupo ng gamot laban sa high blood pressure para sa'yo.

Tea for high blood pressure

Tuberculosis and diseases of the circulatory System

Diseases of the circulatory System-diet-room

A series of exercises for high blood pressure

chinahk-ip.com/chinahk_ip/html/files/editor/6027-definition-of-the-risk-of-cardiovascular-diseases.xml

chaltkirpich.ru/upload/the-risk-of-developing-cardiovascular-diseases.xml

Madalas nagtatanong ang mga tao sa mga botika tungkol sa mga gamot laban sa presyon ng bagong henerasyon na walang side effects. Pero sa totoong buhay, hindi ito nangyayari. Lahat ng epektibong gamot ay may kanya-kanyang side effects. Kailangan mong maglaan ng maraming oras kasama ang iyong doktor para piliin ang tamang grupo ng gamot laban sa high blood pressure para sa'yo. Cardio Balance is formulated and made after years of rigorous research and clinical study of the ingredients. The unique combination of each ingredient brings out optimal effectiveness in supporting heart and blood pressure.

Medicines for high blood pressure in chronic kidney disease: a Phase 3 studyIntroductionHigh blood pressure (arterial hypertension) in patients with chronic kidney disease (CKD) is common and represents a significant risk factor for the progression of kidney damage and cardiovascular events. The effective blood pressure control is considered a key strategy for slowing the progression of the CNE, and to the reduction of cardiovascular morbidity and mortality.ObjectiveThis Phase 3 study aims to investigate the efficacy and tolerability of the newly developed anti-hypertensive drugs in patients with CNE. In particular, the ability of the substances to reduce the glomerular filtration pressure in order to stabilize the renal function should be evaluated.MethodologyStudy type: multicenter, randomized, double-blind, placebo-controlled study.Participants: 500 adult patients aged 18-75 years with a diagnosis of chronic kidney disease (eGFR: 30 to 60\ \text{ml/min/1{,}73\ m^2}), and persistent high blood pressure (mean systolic blood pressure ≥140 mmHg).Intervention: The experimental group receives the newly developed drug (drug class: selective Endothelin‑Receptor Antagonist) in increasing doses (10 mg, 25 mg, 50 mg daily). The control group will receive Placebo.Comparator: standard therapy with ACE inhibitors or AT1‑Receptor blockers.Primary endpoint: change in the eGFR (estimated glomerular filtration rate) after 12 months.Secondary Endpoints:Reduction in systolic and diastolic blood pressure;Change in the proteinuria levels;Incidence of cardiovascular events (myocardial infarction, stroke);The frequency of adverse events and study discontinuations due to toxicity.Observation Period: 24 Months.Results (hypothetical)After 12 months the group that received the new drug showed a significantly lower decrease in the eGFR in comparison to the placebo group (p<0,05). The average reduction in systolic blood pressure was 18.2 mmHg in the intervention group compared to 8.5 mmHg in the placebo group. The proteinuria decreased in the intervention group and 35%, while in the placebo group, a reduction of 10% was found.The frequency of serious side effects (Hyperkalemia, acute renal failure) difference between the groups is not significant. The impact of the new drug was rated as good, with only 5% of the patients had to stop therapy.DiscussionThe results support the hypothesis that the selective Endothelin‑Receptor Antagonist in patients with CKD and hypertension receives the kidneys function better than standard therapy alone. The additional reduction in blood pressure and reduction of proteinuria could exert a protective effect on the kidneys.ConclusionThe study results suggest that the newly developed drug represents a promising Option for the treatment of hypertension in patients with chronic kidney disease. Further long-term studies are required to confirm the cardiovascular Outcomes and the long-term impact.Would you like me to make a certain section in more detail, or to add further Details to one aspect?